New drug cocktail shows promise for rare eye cancer that spreads to liver

NCT ID NCT05542342

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, sitravatinib (a pill) and tislelizumab (an IV infusion), in 16 people with a rare eye cancer (uveal melanoma) that had spread to the liver. The goal was to see if the combo could shrink liver tumors better than current treatments. Participants received the drugs until their disease got worse or side effects became too severe. The study is now complete, and results will show how many patients had their tumors shrink.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA WITH LIVER METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital General Universitario de Valencia

    Valencia, 46014, Spain

  • Hospital Universitario Virgen de la Macarena

    Seville, Andalusia, 41009, Spain

  • Hospital Universitario la Paz

    Madrid, 28046, Spain

  • Institut Catala Oncologia (ICO) L´Hospitalet

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain